The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because deaths from prostate cancer are expected to rise worldwide owing to increased life expectancy and population growth, a final analysis of the long-term outcomes of prostate cancer screening is essential to understanding the benefits and harms of PSA testing.
We updated the findings from ERSPC, a multicenter, randomized study conducted across eight European countries with a focus on a predefined core age group of 162,236 men who were 55 to 69 years of age at the time of randomization. Participants were randomly assigned to the screening group and offered repeated PSA testing or to the control group and not invited for screening. The primary outcome was prostate cancer mortality.
After a median follow-up of 23 years, prostate cancer mortality was 13% lower in the screening group (rate ratio, 0.87; 95% confidence interval [CI], 0.80 to 0.95), and the absolute risk reduction was 0.22% (95% CI, 0.10 to 0.34). The cumulative incidence of prostate cancer was higher in the screening group than in the control group (rate ratio, 1.30; 95% CI, 1.26 to 1.33). At a median of 23 years of follow-up, one death from prostate cancer was prevented for every 456 men (95% CI, 306 to 943) who were invited for screening, and one death from prostate cancer was averted for every 12 men (95% CI, 8 to 26) in whom prostate cancer was diagnosed, as compared with one death from prostate cancer prevented for every 628 men (95% CI, 419 to 1481) and one death averted for every 18 men (95% CI, 12 to 45) at 16 years of follow-up.
Long-term follow-up confirms a sustained reduction in deaths from prostate cancer with PSA testing, alongside an improved harm-benefit ratio. Future screening strategies should adopt risk-based approaches to minimize overdiagnosis while maintaining clinical benefits. (Funded by the Dutch Cancer Society and others; ERSPC ISRCTN registry number, ISRCTN49127736.).
The New England journal of medicine. 2025 Oct 30 [Epub]
Monique J Roobol, Ivo I de Vos, Marianne Månsson, Rebecka A Godtman, Kirsi M Talala, Elly den Hond, Vera Nelen, Arnauld Villers, Gregoire Poinas, Maciej Kwiatkowski, Stephen Wyler, Franz Recker, Donella Puliti, Giuseppe Gorini, Marco Zappa, Alvaro Paez, Marcos Lujan, Chris H Bangma, Teuvo Tammela, Fritz H Schröder, Sebastiaan Remmers, Jonas Hugosson, Anssi Auvinen, ERSPC Investigators
Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Department of Urology, Sahlgrenska Academy at Goteborg University, Gothenburg, Sweden., Cancer Society of Finland, Helsinki., Provincial Institute for Hygiene, Antwerp, Belgium., Department of Urology, Lille, Universite Lille Nord de France, Lille, France., Department of Urology, Clinique Beau Soleil, Montpellier, France., Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland., Oncologic Network, Prevention and Research Institute (ISPRO), Florence, Italy., Department of Urology, Hospital Universitario de Fuenlabrada, Madrid., Department of Urology, Hospital Universitario Infanta Cristina, Madrid., Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Prostate Cancer Research Center, Faculty of Social Sciences, Tampere University, Tampere, Finland.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/41160819
Related Content:
ERSPC 23-Year Update: Long-Term Benefits of PSA Screening - Monique Roobol